Online inquiry

IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2265MR)

This product GTTS-WQ2265MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets F gene. The antibody can be applied in Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Lama glama
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID P03420
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ2265MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8954MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ8331MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HN-66000
GTTS-WQ7001MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ13123MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ12853MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OPN-305
GTTS-WQ6573MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DC-1630423
GTTS-WQ13421MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ11943MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MLTA3698A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW